14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs IMCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Captures Overall Composite Edge (57.8 HOLD vs 46.3 HOLD), While IMCR Leads 4–2 on Growth & Valuation Pillars
VOR Overall Winner
6-Pillar Tally: VOR 2 – 4 IMCR
Matrix Metrics: VOR 6 – 4 IMCR
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (57.8/100 HOLD vs. 46.3/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IMCR wins 4–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.07 (23.8x Forward P/E, -2.2% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. IMCR 46.3/100 HOLD) and 1.91β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs IMCR. Trailing 12-month operating profitability (VOR 0.0% vs IMCR -2.2%) and valuation multiples (VOR N/M vs IMCR 23.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.6B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment36.7% of Rev ($158M)
90D Engineering Disclosures0 Published
Investor FAQ VOR vs IMCR Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (57.8/100 HOLD vs. 46.3/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IMCR wins 4–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.07 (23.8x Forward P/E, -2.2% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. IMCR 46.3/100 HOLD) and 1.91β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMCR leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMCR at -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $429M for IMCR. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus 36.7% of Rev ($158M) (0 disclosures) for IMCR.
IMCR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMCR trades at 23.8x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-1.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus IMCR (-7.9% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.